enlivex

According to market news, Changshou Medicine and the RAIN token asset pool Enlivex announced that they have obtained $21 million in debt financing from the New York institutional fund The Lind Partners.The company stated that it will continue to implement its predictive market token asset pool strategy, adding approximately 3 billion RAIN tokens, which will be used to support the company's operational plans. Enlivex is a Nasdaq-listed company that is developing therapies for joint diseases such as osteoarthritis, while holding a large position in RAIN as part of the RAIN digital asset pool. RAIN is a decentralized predictive market protocol token deployed on the Arbitrum network, which determines outcomes through AI and employs a buyback and burn mechanism. Enlivex's stock price is currently around $1.05, down about 5% for the day.

According to DLnews, Nasdaq-listed company Enlivex announced it will spend $212 million to acquire the native token of Rain Protocol, which is a prediction market protocol launched on the Arbitrum chain in 2023, with a market capitalization of $1.8 billion.This transaction comes at a time when the prediction market is thriving. Kalshi and Polymarket recently completed $1 billion in financing, with valuations reaching $11 billion and $8 billion, respectively. This year, the trading volume in prediction markets has exceeded $28 billion, and it is expected to reach $95.5 billion within ten years.However, regulatory pressure is increasing. Regulatory agencies in various U.S. states have accused these platforms of operating without a license for gambling, and Kalshi has received seven injunctions this year. Polymarket, on the other hand, received CFTC approval to return to the U.S. market on November 25.

According to The Block, Nasdaq-listed company Enlivex plans to raise $212 million to establish a treasury for the Rain token, stating that it will become the first DAT company built on a prediction market token.Rain is a decentralized prediction market protocol on the Arbitrum network that allows anyone to create markets and trade customized options on any event in any language, with results resolved by artificial intelligence, and features a buyback and burn mechanism linked to the RAIN token.

ChainCatcher news, Israeli clinical-stage immunotherapy company Enlivex Therapeutics announced that its board has approved the allocation of up to $1 million for the purchase of Bitcoin as part of its cash management strategy.The company is listed on the NASDAQ in the United States (ticker: ENLV). CEO Oren Hershkovitz stated that with the growing demand and acceptance of Bitcoin, along with the recent approval of Bitcoin ETFs and support from institutional investors, the company believes that Bitcoin can serve as a strong asset reserve, providing value storage and anti-inflation capabilities.